ArticleACS nano2009
Vault nanoparticles containing an adenovirus-derived membrane lytic protein facilitate toxin and gene transfer.
Article in ACS nano, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 46 citations in OpenAlex.
- Review
- Tailored Functionalized Protein Nanocarriers for Cancer Therapy: Recent Developments and Prospects.Pharmaceutics · 2023Review
- Manufacturing of non-viral protein nanocages for biotechnological and biomedical applications.Frontiers in bioengineering and biotechnology · 2023Review
- Article
- Review
- Intratumor injection of CCL21-coupled vault nanoparticles is associated with reduction in tumor volume in an in vivo model of glioma.Journal of neuro-oncology · 2020Article
- Article
- Decrease in pH destabilizes individual vault nanocages by weakening the inter-protein lateral interaction.Scientific reports · 2016Article
- Virus-Surface-Mimicking Surface Clustering of AuNPs onto DNA-Entrapped Polymeric Nanoparticle for Enhanced Cellular Internalization and Nanocluster-Induced NIR Photothermal Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2015Article
- Vault nanoparticles engineered with the protein transduction domain, TAT48, enhances cellular uptake.Integrative biology : quantitative biosciences from nano to macro · 2013Article
- Engineered mutations change the structure and stability of a virus-like particle.Biomacromolecules · 2012Article
- Applications of viral nanoparticles in medicine.Current opinion in biotechnology · 2011Review
- Targeted vault nanoparticles engineered with an endosomolytic peptide deliver biomolecules to the cytoplasm.ACS nano · 2011Article
- Vaults engineered for hydrophobic drug delivery.Small (Weinheim an der Bergstrasse, Germany) · 2011Article
- Article
- Functional genetic and biophysical analyses of membrane disruption by human adenovirus.Journal of virology · 2011Article
- Vaults are dynamically unconstrained cytoplasmic nanoparticles capable of half vault exchange.ACS nano · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Nonviral methods of gene delivery possess several advantages over that of viral-based vectors, including having increased safety. However, the ability to achieve effective transport of therapeutic molecules across host cell membranes via nonviral methods remains a significant goal. Cell-derived nanoparticles known as vaults have been proposed as novel candidate transfer vehicles for various foreign molecules. Recombinant vault particles enter cells via macropinocytosis or phagocytosis but lack demonstrable membrane penetrating activity. To explore the feasibility of improving vault penetration into target cells, we incorporated the membrane lytic domain of adenovirus protein VI (pVI) into the interior of recombinant vault particles via fusion to the vault poly(ADP-ribose) polymerase (VPARP) interaction domain. The membrane lytic activity of the pVI domain was retained upon incorporation into vault particles. Moreover, internalization of vault-pVI complexes into murine macrophages promoted co-delivery of a soluble ribotoxin or a cDNA plasmid encoding GFP. These findings indicate that vault particles can be modified to enhance cell transfer of selected biomolecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.